UGMLC focuses on translational research of lung diseases triggered by inflammatory and hyperprolific processes. This encompasses the pre- and postnatal influence of environmental factors on the development of asthma and chronic obstructive lung disease (COPD) with regard to airways as well as vessels.
Researchers of the Disease Area pneumonia and acute lung injury (ALI) explore the role of innate immunity and mechanisms of inflammation during acute illness and the healing and repair process.
In the Disease Areas lung fibrosis (DPID) and pulmonary hypertension (PH) molecular and cellular mechanisms are investigated, which should help to develop effective regenerative therapies.
The partners of UGMLC complement each other through interplay between basic research and clinical research, which is attained by the integration of the Max Planck Institute, the universities and the hospital. Marburg focuses on asthma and COPD, Giessen on the fields of DPLD and PH as Giessen is a national and international center for these diseases. The Max Planck Institute in Bad Nauheim focuses on stem cell research, developmental biology and cellular signal transduction.
Further synergies a created in cooperation with other locations of DZL and other networks (e.g. AsCoNet: competence network asthma and COPD; COSYCONET: German COPD and systemic consequences – comorbidities network) as well as local research collaborations such as the Cluster of Excellence on the cardio-pulmonary system (ECCPS).
Director of UGMLC is Prof. Dr. Werner Seeger. He is supported by Dr. Sylvia Weissmann as manager.